research Identifying SARS-CoV-2 entry inhibitors through drug repurposing screens of SARS-S and MERS-S pseudotyped particles
Six existing drugs may help block virus entry in COVID-19.
Search
for
Sort by
Research
480-510 / 1000+ resultsresearch PD59-09 PHOSPHODIESTERASE INHIBITORS COULD REVERSE THE PROLIFERATION OF BPH EPITHELIAL CELLS INDUCED BY CD8+ T CELLS IN LOW ANDROGEN CONDITION
Phosphodiesterase inhibitors like tadalafil can reduce cell growth in BPH caused by CD8+ T cells in low androgen conditions.
research EFFECTS OF FESOTERODINE, A NOVEL ANTIMUSCARINIC, ALONE AND IN COMBINATION WITH AN α-RECEPTOR BLOCKER, DOXAZOSIN, ON BLADDER FUNCTION IN OBSTRUCTED RATS
Combination therapy with fesoterodine and doxazosin improves bladder function and delays BPH progression.
research JAK-inhibitors in the therapy of comorbid diseases – atopic dermatitis and alopecia areata: literature review and experience of clinical practice
JAK inhibitors effectively treat severe atopic dermatitis and alopecia areata.
research [Prophylaxis of recurring low-flow priapism : Experimental botulinum neurotoxin injection into the ischiocavernosus muscle].
Botulinum neurotoxin injections into the pelvic muscles successfully prevented priapism relapse for over six months.
research Novel inhibitors of 5α-reductase
New research is needed to create better drugs that block the enzyme responsible for conditions like male baldness and prostate enlargement.
research Results of Ifosfamide Combination Chemotherapy in Patients with Advanced Soft Tissue Sarcomas
Adriamycin and ifosfamide together work best for advanced soft tissue sarcomas.
research Jak inhibitors in the treatment of alopecia areata - a literature review
Oral JAK inhibitors show promise for treating alopecia areata but have challenges like relapse and side effects.
research Combined Low Dose Oral Minoxidil and Immunomodulator Efficacy and Safety in Alopecia Areata: A Systematic Review
Combining low-dose oral minoxidil with immunomodulators shows promise for treating alopecia areata but needs more research.
research Disease Prevention and Alleviation by Human Myoblast Transplantation
Myoblast transplantation shows promise for treating various muscle and heart conditions.
research Computer-Aided Designing Peptide Inhibitors of Human Hematopoietic Prostaglandin D2 Synthase Combined Molecular Docking and Molecular Dynamics Simulation
Two peptides, RMYYY and VMYMI, may be effective anti-inflammatory drugs.
research 860 Understanding cellular & molecular responses in the treatment of pediatric lymphatic anomalies
Sirolimus and propranolol may reduce abnormal cell growth and improve lymphatic malformations in children.
research Inhibitory effect of M50054, a novel inhibitor of apoptosis, on anti-Fas-antibody-induced hepatitis and chemotherapy-induced alopecia
M50054 may help treat hepatitis and hair loss from chemotherapy.
research JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis
JAK inhibitors are effective in treating various immune-related diseases, not just rheumatoid arthritis.
research Janus kinase inhibitors for alopecia areata: A narrative review
Janus kinase inhibitors can regrow hair in alopecia areata but may cause side effects and hair loss may return if treatment stops.
research Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis
Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.
research New 5?-reductase inhibitors: In vitro and in vivo effects
Four new compounds were more effective than finasteride in treating prostate issues and hair loss, with one being 100 times more active and safe for use.
research K channel therapeutics at the bedside
Potassium channel openers are effective in treating heart conditions, high blood pressure, pulmonary diseases, bladder issues, and hair loss, but more selective drugs are needed.
research Most recent findings of curative drugs for lower urinary tract symptoms in clinical practice
Current treatments for lower urinary tract symptoms include α1-blockers, 5ARIs, PDE5 inhibitors, anticholinergic agents, and β3-adrenergic receptor agonists.
research The Role of the Mammalian Target of Rapamycin (mTOR) in Pulmonary Fibrosis
mTOR inhibitors may help treat lung fibrosis.
research Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
JAK inhibitors may help treat Alopecia Areata but need careful monitoring due to side effects.
research PC-SPES Studies Promising, But Manufacturer Shuts Down
Promising cancer treatments were found, but the manufacturer closed.
research Design, Synthesis, and Biological Characterization of Metabolically Stable Selective Androgen Receptor Modulators
Researchers developed new compounds that target the androgen receptor effectively with fewer side effects.
research Studies on lysosomes—XIII
Stilbamidine and hydroxystilbamidine inhibit enzyme release from lysosomes and have effects similar to cortisol and chloroquine.
research Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea
Lenvatinib and sorafenib are generally safe but need dose adjustments due to side effects.
research Clinical Snippets
Early sunburn treatment with certain inhibitors may reduce skin cancer risk.
research Dual inhibitors of urease and carbonic anhydrase-II from Iris species
Some natural compounds from Iris plants can block enzymes related to certain disorders, with a few affecting both targeted enzymes.
research Protein kinase C is a key target for attenuation of Leigh syndrome by rapamycin
Rapamycin may help treat Leigh syndrome by targeting protein kinase C.
research Effect of MK-386, a novel inhibitor of type 1 5 alpha-reductase, alone and in combination with finasteride, on serum dihydrotestosterone concentrations in men
research Design, synthesis and anti-tumor evaluation of novel thiohydantoin congeners as androgen receptor antagonists with in vivo study.
A new compound, 3a, effectively fights prostate cancer better than finasteride.